Available Technology

Ketamine Metabolites for the Treatment of Depression and Pain

The market continues to have a need for therapeutics for treating pain and depression that have efficacy in a high percentage of patients but have reduced anaesthetic properties and reduced abuse liability. Ketamine, a drug currently used in human anesthesia and veterinary medicine, has been shown in clinical studies to be effective in the treatment of several conditions, including the of treatment-resistant bipolar depression, major depressive disorder, neuropathic pain, and chronic pain, including complex regional pain syndrome (CRPS). However the routine use of the drug is hindered by unwanted central nervous system (CNS) effects and a patient response rate of ~70%. New data suggests that ketamine metabolites can be used with similar results but with an increase in patient response rates and a decrease in undesirable side effects.
Abstract: 
The market continues to have a need for therapeutics for treating pain and depression that have efficacy in a high percentage of patients but have reduced anaesthetic properties and reduced abuse liability. Ketamine, a drug currently used in human anesthesia and veterinary medicine, has been shown in clinical studies to be effective in the treatment of several conditions, including the of treatment-resistant bipolar depression, major depressive disorder, neuropathic pain, and chronic pain, including complex regional pain syndrome (CRPS). However the routine use of the drug is hindered by unwanted central nervous system (CNS) effects and a patient response rate of ~70%. New data suggests that ketamine metabolites can be used with similar results but with an increase in patient response rates and a decrease in undesirable side effects.
Benefits: 
Increased number of patients able to respond to the treatment because it bypasses the human metabolic machinery needed to convert the drug into its active metabolite(s). - Decreased CNS side effects.
applications: 
Inventors: 

Ruin Moaddel (NIA)

Irving Wainer (NIA)

Carlos Zarate (NIMH)

Patent Number: 
61/547,336 PCT Application No. PCT/US12/60256 US A
Internal Laboratory Ref #: 
E-092-2011/0 Updated: Nov 9, 2015
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin